# Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia

> **NCT05233124** · PHASE2 · UNKNOWN · sponsor: **Instituto Nacional de Cardiologia Ignacio Chavez** · enrollment: 60 (estimated)

## Conditions studied

- Acute Coronary Syndrome
- Coronary Artery Ectasia

## Interventions

- **DRUG:** Rivaroxaban 15 MG
- **DRUG:** Acetylsalicylic acid 100mg
- **DRUG:** Clopidogrel 75 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT05233124
- **Lead sponsor:** Instituto Nacional de Cardiologia Ignacio Chavez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233124, "Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05233124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*